Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Foa

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Haematologica|May 1, 1990
1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosisP Foa, A T Maiolo, M Cortellaro, et al.
Tumori|July 30, 1999
[Adjuvant therapy of colon cancer. State of the art and future perspectives]S Barni, S Cascinu, P Foa, et al.
Haematologica|November 1, 1987
Biological characterization of refractory anemia with excess of blastsA T Maiolo, P Foa, D Pagetti, et al.
Haematologica|January 1, 1987
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemiaA T Maiolo, P Foa, M Cortellaro, et al.
Oncology|August 21, 2008
Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II studyD Ferrari, F Chiesa, C Codecà, et al.
The International Journal of Biological Markers|July 10, 1999
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancerP Foa, M Fornier, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu, R Labianca, V Catalano, et al.
Blood|June 20, 1998
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid MetaplasiaG Barosi, A Ambrosetti, A Centra, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 24, 2011
Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patientsF Alongi, M Bignardi, I Garassino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studyA Santoro, V Gebbia, T Pressiani, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Haematologica|May 1, 1990
1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosisP Foa, A T Maiolo, M Cortellaro, et al.
Tumori|July 30, 1999
[Adjuvant therapy of colon cancer. State of the art and future perspectives]S Barni, S Cascinu, P Foa, et al.
Haematologica|November 1, 1987
Biological characterization of refractory anemia with excess of blastsA T Maiolo, P Foa, D Pagetti, et al.
Haematologica|January 1, 1987
Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemiaA T Maiolo, P Foa, M Cortellaro, et al.
Oncology|August 21, 2008
Locoregionally advanced nasopharyngeal carcinoma: induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin: a phase II studyD Ferrari, F Chiesa, C Codecà, et al.
The International Journal of Biological Markers|July 10, 1999
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancerP Foa, M Fornier, R Miceli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu, R Labianca, V Catalano, et al.
Blood|June 20, 1998
Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid MetaplasiaG Barosi, A Ambrosetti, A Centra, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|December 24, 2011
Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patientsF Alongi, M Bignardi, I Garassino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2014
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh studyA Santoro, V Gebbia, T Pressiani, et al.
Pageof 9